1. “Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice” Int J Pharma. 2026, 694:126752. (https://doi.org/10.1016/j.ijpharm.2026.126752) (影響因子為 5.2，在藥學與藥理學領域 366 種期刊中，引用次數排名第 3)
2. “TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity” Haematologica. 2025, Nov 6. (https://doi.org/10.3324/haematol.2025.288692) (影響因子為 7.9，在血液學領域約 75–120 種期刊中排名第 8 至第 10 )
3. “2FA-platform generates dual fatty acid-conjugated GLP‑1 receptor agonist TE-8105 with enhanced diabetes, obesity, and NASH efficacy compared to semaglutide” J. Med. Chem. 2025, 68, 6178-6192. (https://doi.org/10.1021/acs.jmedchem.4c02153) (影響因子為 6.8，在藥物化學領域 72 種期刊中排名第 3)
4. “An antibody-drug conjugate for multiple myeloma prepared by multi-arm linkers” Adv. Sci. 2024, 2307852. (https://doi.org/10.1002/advs.202307852) (影響因子為 14.1，在奈米科學與奈米技術領域期刊中位居前 7–8%)
5. “Site-specific conjugation of 6 DOTA chelators to a CA19-9-targeting scFv-Fc antibody for imaging and therapy” J. Med. Chem. 2023, 66, 10604-10616. (https://doi.org/10.1021/acs.jmedchem.3c00753) (影響因子為 6.8，在藥物化學領域 72 種期刊中排名第 3)